The client’s objective was to identify and prioritise opportunities to shape external policy moving forward. The project aimed to understand what government and regulatory bodies had already done about PM, what committees were in place, and how the pharmaceutical/diagnostic stakeholders were working together. In the first instance it was necessary to define some key questions to address with the target stakeholders. Through a series of structured interviews, our focus was to understand what importance PM held from a health policy perspective and the main hurdles slowing the progress of PM. In particular, HTA bodies such as NICE slowing the progress of PM, plus the separate assessment of diagnostic tools and pharmaceuticals etc by HTA bodies.
